Last €53.20 EUR
Change Today +0.10 / 0.19%
Volume 2.8K
As of 11:35 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

stallergenes (GENP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/14 - €63.46
52 Week Low
12/8/14 - €46.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STALLERGENES (GENP)

Related News

No related news articles were found.

stallergenes (GENP) Related Businessweek News

No Related Businessweek News Found

stallergenes (GENP) Details

Stallergenes S.A. operates as a pharmaceutical laboratory that specializes in the diagnosis and treatment of allergies in France and internationally. It provides targeted therapeutic solutions of allergenic immunotherapy to improve the lives of patients suffering from allergies. The company offers specialties and APSI products, as well as diagnostic products. It sells its products in approximately 75 countries. The company was founded in 1962 and is based in Antony, France.

1,019 Employees
Last Reported Date: 07/25/14
Founded in 1962

stallergenes (GENP) Top Compensated Officers

Deputy Chief Executive Officer
Total Annual Compensation: €159.0K
Compensation as of Fiscal Year 2013.

stallergenes (GENP) Key Developments

Stallergenes S.A. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 11:00 AM

Stallergenes S.A. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 11:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Christian Chavy, Chief Executive Officer, Director, Member of Executive Management Committee, Member of Audit Committee and Member of Strategic & Corporate Development Committee.

Stallergenes S.A. Presents at Oddo Midcap Forum, Jan-08-2015

Stallergenes S.A. Presents at Oddo Midcap Forum, Jan-08-2015 . Venue: Lyon’s Convention Center, Lyon, France.

Stallergenes S.A. and ActoGeniX NV to Develop Innovative New Class of Oral Allergy Treatments

Stallergenes S.A. announced that it has exercised the option to pursue the exclusive development of an innovative new class of oral allergy treatments in partnership with ActoGeniX NV in accordance with the contract signed in December 2013. The collaboration centers on the development of a novel treatment approach based on allergen-specific tolerance through innovative delivery of allergens expressed and secreted by the allergen-secreting L.lactis bacteria. Stallergenes and ActoGeniX have successfully conducted a Proof of Principle study in preclinical models to validate the application of ActoGeniX's technology to allergens. On December 2, 2013, STALLERGENES and ActoGeniX entered into an agreement for the development of innovative first-in-class treatments of allergic diseases. Under the terms of this agreement, ActoGeniX is responsible for the creation of clinical product candidates based on the application of ActoBiotics genetically engineered lactic acid bacteria to a set of allergens defined by Stallergenes. STALLERGENES will have full development and exclusive worldwide commercialization rights to such clinical product candidates, and ActoGeniX will be eligible to receive preclinical, clinical, regulatory and commercial payments if certain milestones are reached, totaling up to EUR 75 million per allergen, as well as tiered royalties on the future product's net sales.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENP:FP €53.20 EUR +0.10

GENP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr773.00 DKK +19.00
Allergy Therapeutics PLC 24.00 GBp 0.00
DBV Technologies SA €45.22 EUR +0.26
Merck & Co Inc $62.23 USD -0.33
Sanofi €81.99 EUR +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation GENP Industry Range
Price/Earnings 14.7x
Price/Sales 2.4x
Price/Book 2.4x
Price/Cash Flow 14.8x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STALLERGENES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at